Arvinas reports positive phase 1 data for Parkinson's drug ARV-102

March 18, 2026 7:00 AM

Arvinas Inc. (NASDAQ: ARVN) reported positive results from a phase 1 clinical trial of ARV-102, an experimental drug for Parkinson's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found